Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 2/20 | 0.41 |
| ▸ | PPARD | Q03181 | 6/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3970700 | 0.87 | HTR2A (0.55) | HTR2AHTR2CFFAR1PPARAPPARD | |
| SCHEMBL3967932 | 0.87 | HTR2A (0.55) | HTR2AHTR2CFFAR1PPARAPPARD | |
| SCHEMBL3967933 | 0.87 | HTR2A (0.55) | HTR2AHTR2CFFAR1PPARAPPARD | |
| SCHEMBL3964811 | 0.82 | FFAR1 (0.63) | FFAR1PPARAPPARD | |
| SCHEMBL3964872 | 0.80 | THRA (0.38) | HTR2AHTR2CPPARAPPARDHSD17B1 | |
| SCHEMBL3970689 | 0.80 | HSD17B1 (0.37) | FFAR1PPARAPPARDHSD17B1 | |
| SCHEMBL3965573 | 0.79 | POLB (0.41) | HTR2AHTR2CPPARDHSD17B1 | |
| SCHEMBL3964420 | 0.78 | HSD17B1 (0.44) | HTR2AHTR2CPPARAPPARDHSD17B1 | |
| SCHEMBL13110418 | 0.75 | FFAR1 (0.59) | FFAR1PPARAPPARD | |
| SCHEMBL21538693 | 0.75 | NQO2 (0.56) | PPARAPPARDHSD17B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2006271-A9 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2009-07-29 | — | — | EP | disclosed |
| CN-101410366-A | Substituted bicyclic ring derivatives and uses thereof | ASAHI KASEI PHARMA CORP (JP) | 2009-04-15 | — | — | CN | disclosed |
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| EP-2006271-A2 | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF | Asahi Kasei Pharma Corporation (JP) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054401-A1 | Substituted bicyclic derivatives and use thereof | LTB4R2, LTC4S, LTB4R | HTR2A 760/4885HTR2C 716/4885FFAR1 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.